{
  "trial_id": "NCT02724020",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, histological confirmation of renal cell carcinoma, Karnofsky Performance Status (KPS), prior lines of VEGF-targeted therapy, life expectancy, absolute neutrophil count, platelet count, alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, total bilirubin levels, estimated creatinine clearance, glycosylated hemoglobin (HbA1c) levels, fasting serum glucose levels, fasting triglycerides levels, time since last VEGF-targeted treatment, time since last dose of bevacizumab or other antibody or interferon, presence of CNS metastasis, presence of other significant comorbidities, HIV status, hepatitis B and C status, history of gastrointestinal surgery or disease, pregnancy or breastfeeding status, history of ischemic myocardial or cerebrovascular events, requirement for inotropic support, history of serious cardiac arrhythmia, presence of pacemaker, New York Heart Association heart failure class, history of pulmonary embolism, presence of significant cardiovascular or pulmonary disease, history of arrhythmia requiring an implantable cardiac defibrillator, baseline QTc interval, history of other malignancies, prior therapy with PI3K, AKT, or mTOR inhibitors, hypersensitivity to everolimus or rapamycin derivatives, serious medical or psychiatric illness, use of proton pump inhibitors.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "histological confirmation of renal cell carcinoma",
        "Karnofsky Performance Status (KPS)",
        "prior lines of VEGF-targeted therapy",
        "life expectancy",
        "absolute neutrophil count",
        "platelet count",
        "alanine aminotransferase (ALT) levels",
        "aspartate aminotransferase (AST) levels",
        "total bilirubin levels",
        "estimated creatinine clearance",
        "glycosylated hemoglobin (HbA1c) levels",
        "fasting serum glucose levels",
        "fasting triglycerides levels",
        "time since last VEGF-targeted treatment",
        "time since last dose of bevacizumab or other antibody or interferon",
        "presence of CNS metastasis",
        "presence of other significant comorbidities",
        "HIV status",
        "hepatitis B and C status",
        "history of gastrointestinal surgery or disease",
        "pregnancy or breastfeeding status",
        "history of ischemic myocardial or cerebrovascular events",
        "requirement for inotropic support",
        "history of serious cardiac arrhythmia",
        "presence of pacemaker",
        "New York Heart Association heart failure class",
        "history of pulmonary embolism",
        "presence of significant cardiovascular or pulmonary disease",
        "history of arrhythmia requiring an implantable cardiac defibrillator",
        "baseline QTc interval",
        "history of other malignancies",
        "prior therapy with PI3K",
        "AKT",
        "or mTOR inhibitors",
        "hypersensitivity to everolimus or rapamycin derivatives",
        "serious medical or psychiatric illness",
        "use of proton pump inhibitors"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Karnofsky Performance Status, Histological subtype, Number of prior lines of therapy, Prior VEGF-targeted therapy, Laboratory values (e.g., neutrophil count, platelet count, ALT, AST, bilirubin, creatinine clearance, HbA1c, fasting serum glucose, fasting triglycerides), ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Karnofsky Performance Status",
        "Histological subtype",
        "Number of prior lines of therapy",
        "Prior VEGF-targeted therapy",
        "Laboratory values (e.g., neutrophil count, platelet count, ALT, AST, bilirubin, creatinine clearance, HbA1c, fasting serum glucose, fasting triglycerides)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Karnofsky Performance Status, Number of Prior Lines of Systemic Therapy, Prior VEGF-Targeted Therapy, Time Since Last Dose of Prior Systemic Therapy, Baseline Tumor Size, Baseline Hemoglobin, Baseline Platelet Count, Baseline Absolute Neutrophil Count, Baseline Creatinine Clearance, Baseline Alanine Aminotransferase, Baseline Aspartate Aminotransferase, Baseline Total Bilirubin.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Karnofsky Performance Status",
        "Number of Prior Lines of Systemic Therapy",
        "Prior VEGF-Targeted Therapy",
        "Time Since Last Dose of Prior Systemic Therapy",
        "Baseline Tumor Size",
        "Baseline Hemoglobin",
        "Baseline Platelet Count",
        "Baseline Absolute Neutrophil Count",
        "Baseline Creatinine Clearance",
        "Baseline Alanine Aminotransferase",
        "Baseline Aspartate Aminotransferase",
        "Baseline Total Bilirubin"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, Karnofsky Performance Status (KPS), life expectancy, number of prior lines of systemic therapy, prior VEGF-targeted therapy, histological confirmation of clear-cell renal cell carcinoma, presence of metastases, radiologic evidence of progressive disease, laboratory values (absolute neutrophil count, platelet count, ALT, AST, total bilirubin, estimated creatinine clearance, glycosylated hemoglobin, fasting serum glucose, fasting triglycerides).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Karnofsky Performance Status (KPS)",
        "life expectancy",
        "number of prior lines of systemic therapy",
        "prior VEGF-targeted therapy",
        "histological confirmation of clear-cell renal cell carcinoma",
        "presence of metastases",
        "radiologic evidence of progressive disease",
        "laboratory values (absolute neutrophil count, platelet count, ALT, AST, total bilirubin, estimated creatinine clearance, glycosylated hemoglobin, fasting serum glucose, fasting triglycerides)"
      ]
    }
  }
}